Company news
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) news
Amneal Pharmaceuticals, Inc. news releases on 6ix. Latest, Oct 8, 2026: Amneal to Report Third Quarter 2026 Results on November 3, 2026
Press releases & updates
Amneal to Report Third Quarter 2026 Results on November 3, 2026
October 7, 2026
Amneal Announces FDA Approval and Launch of Lanreotide Injection
September 18, 2026
Amneal Completes Acquisition Of Kashiv
August 17, 2026
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
August 10, 2026
Amneal Reports Second Quarter 2026 Financial Results
July 29, 2026
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
July 17, 2026
Amneal to Report Second Quarter 2026 Results on July 30, 2026
July 9, 2026
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
June 9, 2026
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
June 5, 2026
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
June 4, 2026
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 1, 2026
Amneal Agrees To Acquire Kashiv BioSciences For Total Payment Up To $1.1 Billion
May 11, 2026
Amneal Reports First Quarter 2026 Financial Results
May 7, 2026
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
April 22, 2026
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
April 22, 2026
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
April 20, 2026
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
April 13, 2026
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
April 8, 2026
Amneal to Report First Quarter 2026 Results on May 1, 2026
April 7, 2026
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
April 6, 2026
Amneal Pharmaceuticals : LLC Issues Voluntary Nationwide Recall of Magnesium Sulfate in Water for Injection, USP 4 g/100mL (NDC 70121-1720-3) due to a Product Mix-up with Tranexamic Acid in 0.7% Sodium Chloride Injection, 10 mg/mL
March 24, 2026
Amneal to Participate in Upcoming Investor Conference
March 5, 2026
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
January 28, 2026
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
January 27, 2026
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
December 21, 2025
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
December 8, 2025
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
December 4, 2025
Amneal to Participate in Upcoming Investor Conferences
December 2, 2025
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
December 1, 2025
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
November 30, 2025
Amneal Receives U.S. FDA Approval for Iohexol Injection
November 12, 2025
Amneal Reports Third Quarter 2025 Financial Results
October 29, 2025
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
October 28, 2025
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
October 26, 2025
Amneal to Report Third Quarter 2025 Results on October 30, 2025
September 30, 2025
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
September 25, 2025
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
September 22, 2025
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
September 10, 2025
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
September 3, 2025
Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico
August 5, 2025
Amneal Reports Second Quarter 2025 Financial Results
August 4, 2025
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
July 20, 2025
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
July 20, 2025
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada
July 18, 2025
Amneal to Report Second Quarter 2025 Results on August 5, 2025
July 9, 2025
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
June 25, 2025
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
June 11, 2025
Amneal to Participate at Upcoming Investor Conferences in June
May 29, 2025
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
May 14, 2025